Skip to main navigation

Contact

CLOSE X

About Aimmune
Our Product
- Our Product
- Expanded Access Policy
Our Pipeline
- Our Pipeline
- Our Focus
Media
- Press Releases
Careers
- Career Opportunities

Contact

Press Releases

Keyword Search

Items Per Page

Year

Recent News

March 13, 2020

Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment

February 27, 2020

Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights

February 26, 2020

Aimmune Therapeutics to Present at Upcoming Investor Conferences

February 25, 2020

Aimmune to Present New Clinical Data at AAAAI Annual Meeting

February 20, 2020

Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

February 5, 2020

Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science

February 5, 2020

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

January 31, 2020

FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy

January 6, 2020

Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Media Contacts

Julie Normart
559-974-3245
jnormart@w2ogroup.com

Lauren Barbiero
646-564-2156
lbarbiero@w2ogroup.com

About Aimmune

Company Overview
History
Leadership
Culture of Integrity

Our Product

Our Product
Expanded Access Policy

Our Pipeline

Our Pipeline
Our Focus

Media

Press Releases

Careers

Career Opportunities

© 2020 Aimmune Therapeutics. All rights reserved.

Terms of Use
Privacy Policy
Privacy Shield
Twitter Guidelines
Facebook Guidelines